CymaBay Pipeline

Home / Pipeline

Overview

Our pipeline is focused on developing therapies for liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). Additionally, we have three drug candidates in early development that feature unique mechanisms of action with potential to treat liver and other chronic diseases.

  Pre-Clinical Phase 1 Phase 2 Phase 3
Internal Programs
Seladelpar

(PPARδ agonist)

Primary Biliary Cholangitis
Seladelpar
Non-Alcoholic Steatohepatitis
Seladelpar
Primary Sclerosing Cholangitis
MBX-2982

(GPR 119 agonist)

Diabetic Hypoglycemia
CB-0406

(PPARγ non-agonist ligand)

Inflammation
CB-001

(GPR 120 agonist)

Inflammation